Misuse of Noninferiority Margin: How Much Margin Is Ethical?
- 1 March 2021
- journal article
- letter
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (7), 861-862
- https://doi.org/10.1200/jco.20.02772
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup StudyJournal of Clinical Oncology, 2020
- Challenges in the Design and Interpretation of Noninferiority TrialsThe New England Journal of Medicine, 2017
- A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trialTrials, 2016
- Physicians and knowledge translation of statistics: Mind the gapCMAJ : Canadian Medical Association Journal, 2015
- Statistical Issues and Recommendations for Noninferiority Trials in Oncology: A Systematic ReviewClinical Cancer Research, 2012
- Efficacy of experimental treatments compared with standard treatments in non-inferiority trials: a meta-analysis of randomized controlled trialsInternational Journal of Epidemiology, 2010
- How can research ethics committees protect patients better?BMJ, 2003